Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response
- 20 January 2017
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 98 (4) , 371-377
Abstract
Objectives: To evaluate the efficacy of a salvage treatment with rituximab (RTX) in adults with primary immune thrombocytopenia (ITP), in terms of short‐term response and long‐term response (LTR, i.e., probability to achieve and maintain response) and to identify biological and clinical predictors of response.Methods: We retrospectively evaluated the outcome of patients with primary ITP treated with standard dosage RTX (375 mg/m2 × 4) as salvage therapy in five Italian centers. One hundred and three patients, median age of 46 yr, were included. The median period of observation was 59 months.Results: Response (R) and complete response (CR) were documented in 57 (55%) and 37 (36%) patients, respectively. Patients younger than 40 yr had a higher probability to achieve CR (P = 0.025). Younger women (age < 40 yr) had a significantly higher probability to achieve R and CR (P = 0.039 and P = 0.009, respectively). The estimated LTR rate was 36% and 31% after 48 and 72 months, respectively; female sex (P = 0.033) and younger age (P = 0.021) were associated with better LTR. Younger women had the highest LTR rate (P = 0.006). Response duration was associated with the obtainment of CR after RTX (CR vs. partial response, P = 0.002).Conclusions: The effect of RTX salvage treatment appears higher in younger women, with LTR rate possibly approaching that of splenectomy.Keywords
This publication has 21 references indexed in Scilit:
- Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopeniaBlood, 2013
- Thrombopoietin Receptor Agonists in Primary Immune ThrombocytopeniaSeminars in Hematology, 2013
- Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 yearsHaematologica, 2012
- How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatmentBlood, 2012
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopeniaBlood, 2011
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003
- Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitroBlood, 2003
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994